AzTrials
AzTrials

PAD - Peripheral Arterial DiseaseCLE-PADNCT07469020

CLE-PAD : Prevalence of PAD in Patients With Surgically Lumbar Spinal Stenosis

A study testing contrast-enhanced CT scan in people with PAD - Peripheral Arterial Disease and Lumbar Spinal Stenosis, run by Rennes University Hospital at 3 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this interventional study is to evaluate the rate of existing lower limb peripheral artery disease (PAD) in patients with surgically lumbar spinal stenosis (LSS). PAD and LSS can present similar symptoms and it can be difficult to diagnose PAD using conventional methods, depending on the location of the… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
contrast-enhanced CT scan
Could I receive a placebo?
No, everyone receives an active treatment
How many people
49 participants
Where
3 sitesFrance
Study dates
Aug 2026to Aug 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Presenting with a lumbar spinal stenosis with surgical indication, either unoperated or operated on less than 3 months ago
  • Affiliated with a social security scheme
  • Having received oral and written information about the protocol and having signed a written consent form to participate in this research.

Who cannot join

  • emergency surgical care
  • Contraindication to contrast enhanced CT scan
  • Stroke or myocardial infarction (MI) within the last 3 months
  • Known severe or poorly tolerated arrhythmia
  • Known severe or symptomatic left ventricular outflow obstruction
  • Decompensated heart failure
Show all 11Show fewer
  • History within the last 3 months of venous thromboembolic disease, myopericarditis, endocarditis, aortic dissection or intracardiac thrombus
  • Severe uncontrolled hypertension (BP > 200/110 mmHg)
  • Inability to walk on the treadmill
  • Major lower limb amputation
  • Adult subject to legal protection

Trial locations and contacts

3 sites in 1 country. Contact the study team or a site near you to ask about taking part.

France3 sites, 3 recruiting
  • Groupement des Hôpitaux de l'Institut Catholique de Lille

    Lille

    Marjolaine Talbot, +33320225000, talbot.marjolaine@ghicl.net

    Marjolaine Talbot

    Not yet recruiting
  • Groupe hospitalier Paris Saint Joseph

    Paris

    Ewa Tuleja, +33144127137, etuleja@ghpsj.fr

    Ewa Tuleja

    Not yet recruiting
  • CHU Rennes

    Rennes

    Marie Charasson, +33299284321, marie.charasson@chu-rennes.fr

    Marie Charasson

    Recruiting

Other trials in France

About this study

Official title: CLE-PAD : Prevalence of Lower Extremity Peripheral Artery Disease in Patients With Surgically Lumbar Spinal Stenosis

The goal of this interventional study is to evaluate the rate of existing lower limb peripheral artery disease (PAD) in patients with surgically lumbar spinal stenosis (LSS). PAD and LSS can present similar symptoms and it can be difficult to diagnose PAD using conventional methods, depending on the location of the arterial disease. The main questions it aims to answer are :

  • What's the prevalence of PAD in LSS patients?
  • Which exam among routine tools is the most accurate to diagnose PAD in this population? Around their surgery for LSS (a few weeks before or after), participants will be included in a vascular medicine service. After checking of eligibility criteria, they will undergo a contrast-enhanced CT scan for the diagnosis of PAD and various routine diagnostic tests: Doppler ultrasound, treadmill tests, pressure index, pulse palpation.
Read the detailed description

Lumbar spinal stenosis (LSS) is a debilitating degenerative condition in older people associated with lower back pain, pain in the lower limbs and a reduced quality of life. LSS can be treated surgically, but the results are mixed: 35% of patients report low satisfaction one year after surgery. The symptoms of LSC in the lower limbs can mimic those associated with peripheral arterial disease (PAD). The prevalence of PAD in the LSC population varies between 4.1% and 67.8% depending on the diagnostic tests used and the populations studied. Thus, the precise analysis of the prevalence of PAD and the sensitivity and specificity of PAD diagnostic tests in this population remain to be determined. These analyses would help to optimise PAD diagnostic tools, while possibly providing an explanation for the post-operative persistence of functional discomfort in CLE patients. Furthermore, a better understanding of the vascular system in the CLE population offers hope for optimising patient care, both from a medical and a medico-economic point of view.

The experimental visit takes place as soon as possible after receipt of the biological assessment and within a maximum period of 3 months. During this visit, specific research examinations will be performed, including stress tests (stress TcPO2 according to the modified Strandness protocol and stress TcPO2 according to the Gardner-Skinner increasing load protocol), as well as an injected scan of the aorta of the lower limbs. The pseudonymised CT scan will be sent to the sponsor for blind review. A follow-up telephone call will be made between 7 and 10 days after the CT scan to detect the occurrence of any adverse events. The study will then be completed for the participant.

Being tested
contrast-enhanced CT scan
Medical subject headings
Spinal Stenosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • contrast-enhanced CT scanDiagnostic test

    contrast-enhanced CT scan

Study groups in NCT07469020
Study groupRoleWhat they receive
ParticipantsExperimentalNot described
Receives: Diagnostic Test: contrast-enhanced CT scan

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of patients with PAD identified during the contrast enhanced CT scan

    Number of patients with PAD identified during the contrast enhanced CT scan. PAD will be defined by the presence of at least one arterial stenosis ≥ 50% on the arterial axes located from the abdominal aorta to the origin of the tibiofibular arterial trunk, as determined by CT scan of the aorta and lower limbs in accordance with the recommendations.

    Measured: 3 months

Secondary outcomes (5)
  1. Efficiency of diagnosis test "pulse"

    determination of the sensitivity and specificity, positive predictive value and negative predictive value of the diagnostic test "pulse" : the absence of distal pulses will be considered pathological

    Measured: 3 months

  2. Efficiency of diagnosis test "systolic pressure index"

    determination of the sensitivity and specificity, positive predictive value and negative predictive value of the diagnostic test "systolic pressure index" : A resting systolic pressure index ≤ 0.90 will be considered pathological in accordance with the recommendations.

    Measured: 3 months

  3. Efficiency of diagnosis test "toe systolic pressure index"

    determination of the sensitivity and specificity, positive predictive value and negative predictive value of the diagnostic test "toe systolic pressure index" : A resting toe systolic pressure index ≤ 0.70 will be considered pathological in accordance with the recommendations.

    Measured: 3 months

  4. Efficiency of diagnosis test "Aorto-iliac and lower limb Doppler ultrasound"

    determination of the sensitivity and specificity, positive predictive value and negative predictive value of the diagnostic test "Aorto-iliac and lower limb Doppler ultrasound " : velocimetric criteria for stenosis and Saint-Bonnet B and CD, E and 0 Doppler curves considered pathological (i.e. AOMI) in accordance with recommendations .

    Measured: 3 months

  5. Efficiency of diagnosis test "exercise oxymetry"

    determination of the sensitivity and specificity, positive predictive value and negative predictive value of the diagnostic test "exercise oxymetry " : Delta from rest oxygen pressure (DROP) ≤ -15 mmHg will be considered pathological (i.e. AOMI) in accordance with the recommendations. .

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Mar 2026
  2. Study startAug 2026 (estimated)
  3. Primary completionAug 2026 (estimated)
  4. Study completionAug 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
49 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07469020
Sponsor's protocol ID
35R24_8825_04_CLE-PAD
Acronym
CLE-PAD
Status last verified
Aug 2026
First submitted
9 Mar 2026
Last updated
12 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing contrast-enhanced CT scan in people with PAD - Peripheral Arterial Disease and Lumbar Spinal Stenosis, run by Rennes University Hospital at 3 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 12 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Marie-Laure Gervais (+33299284321, marie-laure.gervais@chu-rennes.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of patients with PAD identified during the contrast enhanced CT scan (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in